2014
Saliva and plasma EGFR studies
Foundational research investigated selected variants in patients with non-small-cell lung cancer (NSCLC).
EGFR RESEARCH
Exploring mutation signals in liquid biopsy.
Explore selected epidermal growth factor receptor (EGFR) mutations and circulating tumor DNA (ctDNA) in plasma and saliva.
MOLECULAR RESEARCH
A target-specific view
of EGFR.
EGFR exon 19 deletions and L858R are among the variants investigated using EFIRM (Electric Field-Induced Release and Measurement). Later work also examines T790M and other study-specific molecular targets.
Circulating tumor DNA (ctDNA) is the tumor-derived fraction of cell-free DNA. Detecting a particular mutation requires an assay designed for that target; it does not provide comprehensive tumor sequencing.
EGFR exon 19 deletionL858RAssay-specific T790M research
Historical EGFR research-kit packaging · not a current kit offering
From proof of concept
to deeper investigation.
2020
Technical characterization
Analytical validation research explored selected assays, sample handling and performance.
2023
Multiplex single-droplet research
A microsensor study investigated ultrashort mutation-containing DNA using a research configuration.
These publications do not establish a universal sensitivity, screening indication or commercially available assay panel. No clinical treatment recommendation is provided.
ASSAY / TARGET / MATRIX / CONFIGURATION
Choose the evidence
that fits your study.
Two primary studies provide useful starting points. Read the full methods, controls and analysis before planning an evaluation.
Plate-based epidermal growth factor receptor (EGFR) assay characterization
- Target
- Four exon 19 deletion variants, L858R and T790M.
- Matrix
- Plasma and saliva assays; analytical dilution experiments used reference DNA.
- Configuration
- EFIRM E-Plate / E-Reader and the published assay protocol.
- Reported result
- The study reports single-digit-copy detection limits for L858R and T790M, versus 5,000 copies for exon 19 deletion. These are assay- and reference-material-specific findings.
This study does not certify current product performance, clinical utility or a universal detection limit.
Read the 2020 studySingle-droplet multiplex EGFR microsensor
- Target
- Synthetic L858R, exon 19 deletion and T790M oligonucleotides.
- Matrix
- Synthetic targets in a model assay; receiver operating characteristic (ROC) analysis here does not measure patient-cohort accuracy.
- Configuration
- The study used a microprinted 96-electrode chip, a custom adapter and an IVIUM multichannel potentiostat. Its results describe that experimental setup, not EFIRM96 product specifications.
- Reported result
- Area under the ROC curve (AUC): 0.98 (L858R), 0.94 (exon 19 deletion), 0.93 (T790M); combined three-target AUC 0.97. AUC is not sensitivity or specificity at a clinical decision threshold.
A research prototype, not a current purchasable kit specification or a validated diagnostic panel.
Read the 2023 studyReviews provide context
The 2025 and 2026 saliva reviews summarize a developing field. They do not add a new product validation or establish a screening indication.
Explore all publicationsDiscuss a research evaluation plan
Bring a non-confidential target, sample matrix, comparator and evaluation objectives.
Research use only. Published target detection without polymerase chain reaction (PCR) uses enzyme-mediated signal generation; it does not copy target DNA. These study results are not specifications for an instrument or assay offered today.
Discuss your EGFR research study.
Tell us your target variant, sample type and study goals.